Amarin Posts Encouraging Vascepa Data In Patients With Peripheral Artery Disease

Amarin Corporation plc AMRN reported new data for Vascepa/Vazkepa (icosapent ethyl) at the American Heart Association (AHA) Scientific Sessions.
The investigators concluded that "Icosapent ethyl 4 g/day significantly reduced total (first and subsequent) primary endpoints by 32%, and trended toward a 22% reduction in first events, in patients with Peripheral Artery Disease (PAD).
Icosapent ethyl provides substantial cardiovascular risk reduction in the high-risk REDUCE-IT population.
Safety was generally consistent with the overall study. Overall tolerability and adverse events were generally similar between icosapent ethyl and placebo.
More atrial fibrillation/flutter occurred with icosapent ethyl versus placebo in patients with prior PAD (5.2% versus 2.6%, respectively).
No differences in bleeding were observed between icosapent ethyl and placebo in patients with prior PAD, likely due to the sample size.
Price Action: AMRN shares are up 4.02% at $4.14 during the market session on the last check Tuesday.